Explore our sister journals here.

Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR Formative Research

Date Submitted: Mar 15, 2022
Date Accepted: Mar 15, 2022

The final, peer-reviewed published version of this preprint can be found here:

Correction: Ascertaining Medication Use and Patient-Reported Outcomes via an App and Exploring Gamification in Patients With Multiple Sclerosis Treated With Interferon β-1b: Observational Study

Limmroth V, Bayer-Gersmann K, Mueller C, Schürks M

Correction: Ascertaining Medication Use and Patient-Reported Outcomes via an App and Exploring Gamification in Patients With Multiple Sclerosis Treated With Interferon β-1b: Observational Study

JMIR Form Res 2022;6(3):e38002

DOI: 10.2196/38002

PMID: 35298393

PMCID: 8972101

Correction: Ascertaining Medication Use and Patient-Reported Outcomes via an App and Exploring Gamification in Patients With Multiple Sclerosis Treated With Interferon β-1b: Observational Study

  • Volker Limmroth; 
  • Kirsten Bayer-Gersmann; 
  • Christian Mueller; 
  • Markus Schürks

ABSTRACT

N/A


 Citation

Please cite as:

Limmroth V, Bayer-Gersmann K, Mueller C, Schürks M

Correction: Ascertaining Medication Use and Patient-Reported Outcomes via an App and Exploring Gamification in Patients With Multiple Sclerosis Treated With Interferon β-1b: Observational Study

JMIR Form Res 2022;6(3):e38002

DOI: 10.2196/38002

PMID: 35298393

PMCID: 8972101

Per the author's request the PDF is not available.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.